Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
暂无分享,去创建一个
R. Motzer | M. Harrison | E. Plimack | B. Redman | B. Rini | T. Kuzel | H. Drabkin | U. Vaishampayan | D. McDermott | K. Margolin | A. Lambert | S. George | H. Hammers | I. Waxman | T. Logan
[1] L. Schwartz,et al. Kidney Cancer. , 2009, Cancer journal.
[2] E. Plimack,et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). , 2014 .
[3] T. Choueiri,et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. , 2014 .
[4] R. Motzer,et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Porta,et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[6] C. Porta,et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[8] R. Carvajal,et al. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy , 2013, Expert opinion on biological therapy.
[9] M. Harrison,et al. Novel immunotherapeutic strategies in development for renal cell carcinoma. , 2013, European urology.
[10] R. Motzer,et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[11] David C. Smith,et al. Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Stevanović,et al. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy , 2013, World Journal of Urology.
[13] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[14] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[15] George Coukos,et al. Cancer immunotherapy comes of age , 2011, Nature.
[16] R. Kelley,et al. Evidence for drugs and biomarkers in oncology guidelines (GLs): A survey of the National Comprehensive Cancer Network (NCCN) colon cancer panel. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Nurieva,et al. Molecular mechanisms of T‐cell tolerance , 2011, Immunological reviews.
[18] A. Belldegrun,et al. Tumor biology and prognostic factors in renal cell carcinoma. , 2011, The oncologist.
[19] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[21] Yoshimasa Tanaka,et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.
[22] L. Zitvogel,et al. Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.
[23] E. Jaffee,et al. Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.
[24] L. Schwartz,et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Wolzt,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[26] G. Zhu,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[27] D. Longo,et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.
[28] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[29] P. Armitage. Tests for Linear Trends in Proportions and Frequencies , 1955 .
[30] E. S. Pearson,et al. THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .
[31] D.,et al. Regression Models and Life-Tables , 2022 .